Clinical trials: Pulmonary Disease, Chronic Obstructive (COPD), open to volunteers
- Condition Pulmonary Disease, Chronic Obstructive (COPD)
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- Trial name
- PRESTO (NCT07082738)
- Testing
- AZD6793
- Where
- 367 sites in United States, Argentina and 22 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD).
- Trial name
- Sirius (NCT07646587)
- Testing
- WIN378
- Where
- 32 sites in United States, Argentina
- Volunteers
- 105 people
- Sponsor
- Windward Bio
Asthma Acute, COPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
- Trial name
- NCT07705737
- Testing
- Rademikibart
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Connect Biopharm LLC
Chronic Obstructive Pulmonary Disease (COPD)
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD
Study investigating the safety, tolerability, pharmacokinetics and early efficacy with KIT2014 over 7 days of treatment in moderate to severe chronic obstructive pulmonary disease patients.
- Trial name
- NCT07668518
- Testing
- KIT2014
- Where
- 3 sites in Australia
- Volunteers
- 36 people
- Sponsor
- Kither Biotech Srl
Chronic Obstructive Pulmonary Disease (COPD), Healthy Participants
A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
This study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple doses of RO7830698 in healthy participants and participants with chronic obstructive…
- Trial name
- NCT07822334
- Testing
- RO7830698
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
COPD, Emphysema
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea…
- Trial name
- BREATHE-3 (NCT06891755)
- Testing
- Apreo BREATHE Airway Scaffold, Optimal Medical Management (OMM)
- Where
- 23 sites in United States, Austria and 3 more
- Volunteers
- 250 people
- Sponsor
- Apreo Health, Inc.
COPD (Chronic Obstructive Pulmonary Disease)
Study That Will Evaluate the Brazilian Population With COPD.
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic…
- Trial name
- SCOPe (NCT06780046)
- Where
- 10 sites in Brazil
- Volunteers
- 693 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, COPD
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.
- Trial name
- ROMEO (NCT07566195)
- Testing
- Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2
- Where
- 13 sites in France
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce…
- Trial name
- MISSION (NCT07587658)
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 754 people
- Sponsor
- Regeneron Pharmaceuticals
COPD (Chronic Obstructive Pulmonary Disease)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
- Trial name
- STRIDE (NCT07612878)
- Testing
- Cohort 1: Dupilumab, Cohort 2: usual care only
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Sanofi
Emphysema or COPD, Emphysema
A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
A study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.
- Conditions
- Emphysema or COPD, Emphysema, COPD
- Trial name
- IAB-2 (NCT07119229)
- Testing
- Implantable Artificial Bronchus
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pulmair Medical, Inc.
Asthma, COPD
Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis
Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry.
- Trial name
- Care4All (NCT07245576)
- Where
- 12 sites in Argentina, Egypt and 5 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- JOURNEY (NCT06878261)
- Testing
- Tezepelumab
- Where
- 284 sites in United States, Argentina and 20 more
- Volunteers
- 990 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease), Chronic Bronchitis
Repeat Treatment With Metered Cryospray in Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
This study is being conducted to determine the safety of repeat metered cryospray (MCS) treatment in patients with COPD with chronic bronchitis previously treated with MCS.
- Trial name
- MCSRETREAT (NCT07468617)
- Testing
- Metered cryospray (MCS)
- Volunteers
- 10 people
- Sponsor
- CSA Medical, Inc.
COPD (Chronic Obstructive Pulmonary Disease)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated…
- Trial name
- THARROS (NCT06283966)
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg
- Where
- 922 sites in United States, Argentina and 35 more
- Volunteers
- 5,250 people
- Sponsor
- AstraZeneca
COPD
Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD
The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.
- Trial name
- NCT05799664
- Testing
- TLD, Standard of care
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Hangzhou Broncus Medical Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD.
- Trial name
- Navigator (NCT07684820)
- Testing
- EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2
- Where
- 22 sites in United States
- Volunteers
- 600 people
- Sponsor
- Expedition Therapeutics, Inc
COPD (Chronic Obstructive Pulmonary Disease)
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function…
- Trial name
- NCT07828353
- Testing
- REGEND001
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Regend Therapeutics
Chronic Obstructive Pulmonary Disease (COPD), Asthma
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety…
- Trial name
- Breztri rPMS (NCT07570394)
- Where
- 10 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease COPD
Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
The OBS19236 is a retrospective and prospective, non-interventional observational study in COPD patients treated with dupilumab as part of routine clinical care.
- Trial name
- AURORA (NCT07380711)
- Where
- 28 sites in France
- Volunteers
- 500 people
- Sponsor
- Sanofi